Singular Genomics - רווח נקי למניה (EPS TTM) OMIC

The limited pricing power of Singular Genomics Systems (OMIC) due to the dominance of industry behemoths is evident in the TTM net income per share distribution, where the figure stood at -34.86. While the strategy to scale the G4 sequencer and drive consumables sales should support growth, losing the technological race is forcing the company to seek alternatives and wind down direct system sales.

For Singular Genomics Systems (OMIC), earnings per share serves as a key indicator for the monetization of its high-tech sequencing ecosystem. This metric is calculated by dividing total annual net income by the total number of outstanding shares. By analyzing the 12-month rolling EPS, investors can see the actual return from the implementation of the G4 platform and the closed-loop reagent system. The trend of this indicator reflects the efficiency of B2B customer retention. The upward trajectory of the curve confirms the biotech business's transition to a stage of sustainable profitability.